CA2022484A1 - 1-(pyridinylamina)-2-pyrrolidinones, procede de preparation et utilisation comme medicaments - Google Patents

1-(pyridinylamina)-2-pyrrolidinones, procede de preparation et utilisation comme medicaments

Info

Publication number
CA2022484A1
CA2022484A1 CA2022484A CA2022484A CA2022484A1 CA 2022484 A1 CA2022484 A1 CA 2022484A1 CA 2022484 A CA2022484 A CA 2022484A CA 2022484 A CA2022484 A CA 2022484A CA 2022484 A1 CA2022484 A1 CA 2022484A1
Authority
CA
Canada
Prior art keywords
pyridinylamino
pyrrolidinones
aryl
medicaments
cycloalkane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2022484A
Other languages
English (en)
Other versions
CA2022484C (fr
Inventor
Richard Charles Effland
David Gordon Wettlaufer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Richard Charles Effland
David Gordon Wettlaufer
Hoechst-Roussel Pharmaceuticals Inc.
Hoechst Marion Roussel, Inc.
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richard Charles Effland, David Gordon Wettlaufer, Hoechst-Roussel Pharmaceuticals Inc., Hoechst Marion Roussel, Inc., Aventis Pharmaceuticals Inc. filed Critical Richard Charles Effland
Publication of CA2022484A1 publication Critical patent/CA2022484A1/fr
Application granted granted Critical
Publication of CA2022484C publication Critical patent/CA2022484C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002022484A 1989-08-02 1990-08-01 1-(pyridinylamina)-2-pyrrolidinones, procede de preparation et utilisation comme medicaments Expired - Fee Related CA2022484C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/388,413 US4994472A (en) 1989-08-02 1989-08-02 1-(pyridinylamino)-2-pyrrolidinones as pain relievers
US388,413 1989-08-02

Publications (2)

Publication Number Publication Date
CA2022484A1 true CA2022484A1 (fr) 1991-02-03
CA2022484C CA2022484C (fr) 2000-10-17

Family

ID=23534027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002022484A Expired - Fee Related CA2022484C (fr) 1989-08-02 1990-08-01 1-(pyridinylamina)-2-pyrrolidinones, procede de preparation et utilisation comme medicaments

Country Status (17)

Country Link
US (1) US4994472A (fr)
EP (1) EP0413191B1 (fr)
JP (1) JPH0674264B2 (fr)
KR (1) KR0164437B1 (fr)
AT (1) ATE109142T1 (fr)
AU (1) AU635051B2 (fr)
CA (1) CA2022484C (fr)
DE (1) DE69011013T2 (fr)
DK (1) DK0413191T3 (fr)
ES (1) ES2059929T3 (fr)
FI (1) FI903818A0 (fr)
IE (1) IE65117B1 (fr)
IL (1) IL95250A (fr)
NO (1) NO903388L (fr)
NZ (1) NZ234724A (fr)
PT (1) PT94878B (fr)
ZA (1) ZA906049B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356908A (en) * 1989-04-21 1994-10-18 E. I. Du Pont De Nemours And Company Fungicidal oxazolidinones
EP0435843B1 (fr) * 1989-12-27 1994-06-15 Monsanto Company Composés substitués de pyridine
AUPM656594A0 (en) * 1994-06-30 1994-07-21 Orbital Engine Company (Australia) Proprietary Limited A method and apparatus relating to control of the operation of an internal combustion engine
JP4109718B2 (ja) * 1996-04-12 2008-07-02 アベンティス・ファーマスーティカルズ・インコーポレイテッド アセチルコリンエステラーゼ阻害剤および鎮痛剤としてのイサチン誘導体
US6100276A (en) * 1996-04-12 2000-08-08 Aventis Pharmaceuticals Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
EP1551387A4 (fr) * 2002-07-02 2007-10-10 Brni Neurosciences Inst Activation de la pkc utilisee pour renforcer la secretion de la sapp-a et pour ameliorer la gognition, au moyen de composes du type bryostatine
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
GB0412019D0 (en) * 2004-05-28 2004-06-30 Novartis Ag Organic compounds
WO2007016202A1 (fr) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Utilisation d'un activateur de pkc seul ou combine a un inhibiteur de pkc pour renforcer la memoire a long terme
CA2873179A1 (fr) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Utilisation de bryostatines et de neristatines pour le traitement de difficulte cognitive attribuable a un traumatisme cranien

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670184A1 (de) * 1967-01-20 1971-01-21 Boehringer Sohn Ingelheim Verfahren zur Herstellung heterocyclisch substituierter Hydrazino-imidazoline-(2)
US4260767A (en) * 1979-12-26 1981-04-07 American Cyanamid Company 2-Pyridylhydrazides
US4324884A (en) * 1980-09-25 1982-04-13 General Electric Company Organic amine catalyzed method for making polyetherimide
US4752610A (en) * 1985-12-04 1988-06-21 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing properties
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines

Also Published As

Publication number Publication date
AU635051B2 (en) 1993-03-11
PT94878A (pt) 1991-04-18
IL95250A0 (en) 1991-06-10
EP0413191A1 (fr) 1991-02-20
IE902786A1 (en) 1991-02-27
DE69011013D1 (de) 1994-09-01
KR910004597A (ko) 1991-03-29
PT94878B (pt) 1997-08-29
ZA906049B (en) 1991-04-24
EP0413191B1 (fr) 1994-07-27
KR0164437B1 (ko) 1999-01-15
AU6000290A (en) 1991-02-07
IL95250A (en) 1994-01-25
NO903388D0 (no) 1990-08-01
DK0413191T3 (da) 1994-10-24
US4994472A (en) 1991-02-19
FI903818A0 (fi) 1990-07-31
JPH0674264B2 (ja) 1994-09-21
NZ234724A (en) 1992-01-29
JPH0368572A (ja) 1991-03-25
NO903388L (no) 1991-02-04
CA2022484C (fr) 2000-10-17
DE69011013T2 (de) 1994-12-22
ATE109142T1 (de) 1994-08-15
ES2059929T3 (es) 1994-11-16
IE65117B1 (en) 1995-10-04

Similar Documents

Publication Publication Date Title
CA2024572A1 (fr) 4-pyrimidinamines et pyrimidinediamines substituees en n, procede depreparation et utilisation comme medicaments
CA2022486A1 (fr) 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-ones, procede de preparation et utilisation en tant que medicaments
CA2022484A1 (fr) 1-(pyridinylamina)-2-pyrrolidinones, procede de preparation et utilisation comme medicaments
AU628201B2 (en) 2,3-dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed